Lipocine Inc. Files DEFA14A Proxy Materials

Ticker: LPCN · Form: DEFA14A · Filed: Apr 21, 2026 · CIK: 0001535955

Sentiment: neutral

Topics: proxy-solicitation, sec-filing, corporate-actions

Related Tickers: LPCN

TL;DR

LPCN filed proxy docs 4/21/26 - watch for shareholder votes.

AI Summary

Lipocine Inc. filed a Definitive Additional Materials (DEFA14A) on April 21, 2026, related to proxy solicitations. The filing includes graphic materials and a complete submission text file, with its principal executive offices located in Salt Lake City, Utah.

Why It Matters

This filing indicates ongoing corporate actions and shareholder communications for Lipocine Inc., which could impact investor decisions and the company's strategic direction.

Risk Assessment

Risk Level: low — This is a routine SEC filing for proxy materials and does not inherently present new financial or operational risks.

Key Numbers

Key Players & Entities

FAQ

What type of SEC filing is this?

This is a DEFA14A filing, which stands for Definitive Additional Materials and Rule 14(a)(12) material, used for proxy solicitations.

When was this filing made?

The filing was made on April 21, 2026.

What is the CIK number for Lipocine Inc.?

The CIK number for Lipocine Inc. is 0001535955.

Where are Lipocine Inc.'s principal executive offices located?

Lipocine Inc.'s principal executive offices are located at 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT 84108.

What are the key document types included in this filing?

The filing includes a DEFA14A document, two graphic files (formdefa14a_001.jpg and formdefa14a_002.jpg), and a complete submission text file.

Filing Details

This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 21, 2026 regarding Lipocine Inc. (LPCN).

View full filing on EDGAR

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on Read The Filing